Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting

18 March 2021

Teleticino – “Facevamo tamponi di massa già da tempo” Intervista a Giorgio Calderari, presidente FIT e Group General Manager di Helsinn

16 March 2021

Creare alleanze produttive per i vaccini – L’opinione del Presidente FIT Giorgio Calderari

26 February 2021

Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety

18 February 2021

Il rebus vaccini, tra ritardi e polemiche sui brevetti – Intervista a Giorgio Calderari, Presidente FIT

15 February 2021

Pharma Boardroom – Interview to Giorgio Calderari – Chairman, Farma Industria Ticino (FIT)

15 February 2021

Modem RSI Rete 1 – Covid: la corsa ai vaccini, intervista al Presidente FIT Giorgio Calderari

4 February 2021

Perché i vaccini sono in ritardo? Intervista a Giorgio Calderari, Presidente di FIT

3 February 2021

Tamponi a tappeto per i lavoratori? Intervista a Giorgio Calderari, Presidente di FIT e Group General Manager di Helsinn

26 January 2021

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

12 January 2021